Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

<div>Kaplan-Meier survival analysis with time to achieve first undetectable viral load as outcome in 123 participants using EFV and RIF regimens, stratified by trial arm (800mg EFV-regimen or 600mg EFV-regimen). ARVT: antiretroviral therapy. The dark shade area shows EFV800’s survival curve confidence band and the light one shows EFV600’s survival curve confidence band (CI=95%). Hazard ratios were calculated as hazard of EFV800 over hazard of EFV600.</div>

BioMed Research International

fig3

Figure 3

Figure 3: Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial 

Figure 3 | Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial 